NO20070907L - Pyrrolo-pyridin kinase modulatorer - Google Patents

Pyrrolo-pyridin kinase modulatorer

Info

Publication number
NO20070907L
NO20070907L NO20070907A NO20070907A NO20070907L NO 20070907 L NO20070907 L NO 20070907L NO 20070907 A NO20070907 A NO 20070907A NO 20070907 A NO20070907 A NO 20070907A NO 20070907 L NO20070907 L NO 20070907L
Authority
NO
Norway
Prior art keywords
pyrrolo
kinase modulators
pyridine
pyridine kinase
modulators
Prior art date
Application number
NO20070907A
Other languages
English (en)
Norwegian (no)
Inventor
William D Arnold
Pierre Bounaud
Andreas Gosberg
Ian Mcdonald
Ruo W Steensma
Mark E Wilson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of NO20070907L publication Critical patent/NO20070907L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
NO20070907A 2004-07-27 2007-02-16 Pyrrolo-pyridin kinase modulatorer NO20070907L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59188704P 2004-07-27 2004-07-27
US59188804P 2004-07-27 2004-07-27
US68351005P 2005-05-19 2005-05-19
PCT/US2005/026792 WO2006015123A1 (en) 2004-07-27 2005-07-27 Pyrrolo-pyridine kinase modulators

Publications (1)

Publication Number Publication Date
NO20070907L true NO20070907L (no) 2007-04-16

Family

ID=35262080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070907A NO20070907L (no) 2004-07-27 2007-02-16 Pyrrolo-pyridin kinase modulatorer

Country Status (15)

Country Link
US (3) US7361763B2 (es)
EP (2) EP1781654A1 (es)
JP (1) JP2008508303A (es)
KR (1) KR20070053237A (es)
AU (1) AU2005269386A1 (es)
BR (1) BRPI0513916A (es)
CA (1) CA2573362A1 (es)
EC (1) ECSP077280A (es)
IL (1) IL180790A0 (es)
MA (1) MA28810B1 (es)
MX (1) MX2007001127A (es)
NO (1) NO20070907L (es)
NZ (1) NZ553267A (es)
TN (1) TNSN07027A1 (es)
WO (1) WO2006015123A1 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
TWI465437B (zh) * 2004-03-30 2014-12-21 Vertex Pharma 適合作為ｊａｋ及其它蛋白質激酶抑制劑之氮雜吲哚
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2573362A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
MX2007012659A (es) 2005-04-13 2008-01-11 Astex Therapeutics Ltd Derivados de hidroxi-benzamida y su uso como inhibidores de hsp90.
CA2608733A1 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
PL1893612T3 (pl) * 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
NZ569899A (en) 2006-01-17 2011-06-30 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2007136790A2 (en) * 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) * 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
KR20090082453A (ko) * 2006-11-01 2009-07-30 버텍스 파마슈티칼스 인코포레이티드 야누스 키나제의 억제제로서 유용한 트리사이클릭 헤테로아릴 화합물
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
HUE026659T2 (en) 2006-11-22 2016-07-28 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
TW200838517A (en) * 2006-12-21 2008-10-01 Vertex Pharma Compounds useful as protein kinases inhibitors
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
AU2007336811A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
MX2009008253A (es) * 2007-01-31 2009-10-12 Vertex Pharma Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
GB0702259D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
GB0702265D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-Azaindole derivatives
MX2009010984A (es) 2007-04-10 2010-01-15 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
US8263585B2 (en) * 2007-05-04 2012-09-11 Novartis Ag Organic compounds
JP2010528991A (ja) * 2007-05-21 2010-08-26 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 複素環式キナーゼ調節因子
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
JP2010532759A (ja) * 2007-07-06 2010-10-14 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物を合成するための方法
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2694275A1 (en) * 2007-07-26 2009-01-29 Novartis Ag Organic compounds
JP2011500806A (ja) * 2007-10-25 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
US8598165B2 (en) * 2007-11-26 2013-12-03 University Of Kansas Morpholines as selective inhibitors of cytochrome P450 2A13
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
NZ590784A (en) 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
CA2731498A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009278442B2 (en) 2008-08-05 2013-09-26 Daiichi Sankyo Company, Limited Imidazopyridin-2-one Derivatives
WO2010017150A1 (en) * 2008-08-05 2010-02-11 Abbott Laboratories Compounds useful as inhibitors of protein kinases
CN102159546A (zh) 2008-08-06 2011-08-17 沃泰克斯药物股份有限公司 氨基吡啶激酶抑制剂
EP2379561B1 (en) 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
JOP20190230A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
FR2941948B1 (fr) 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
WO2010114928A2 (en) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
CA2760705A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
JP5721706B2 (ja) 2009-06-17 2015-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス複製の阻害剤
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2266562A1 (en) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
GB0918924D0 (en) * 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
EP2966075B1 (en) 2009-12-31 2019-02-27 Hutchison Medipharma Limited Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
JP5769733B2 (ja) 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジンキナーゼ阻害剤
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
WO2011133388A1 (en) * 2010-04-19 2011-10-27 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
EP2566481A4 (en) * 2010-05-06 2014-01-22 Merck Sharp & Dohme AS FAAH MODULATORS SUITABLE AZA-INDOL DERIVATIVES
CN103153994B (zh) 2010-05-24 2016-02-10 罗切斯特大学 双环杂芳基激酶抑制剂及使用方法
US8779150B2 (en) * 2010-07-21 2014-07-15 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
JP6113151B2 (ja) 2011-05-17 2017-04-12 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013052355A1 (en) 2011-10-03 2013-04-11 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
LT2970265T (lt) * 2013-03-15 2018-09-25 Plexxikon Inc. Heterocikliniai junginiai ir jų panaudojimas
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN104119331B (zh) * 2013-04-26 2018-02-06 广东东阳光药业有限公司 烯基化合物及其使用方法和用途
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
CN105849100B (zh) 2013-11-13 2019-07-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
SI3421468T1 (sl) 2013-11-13 2021-03-31 Vertex Pharmaceuticals Incorporated Postopki za pripravo inhibitorjev replikacije virusov influence
MX2017009571A (es) * 2015-01-23 2018-09-27 Aclaris Therapeutics Inc Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
KR101660863B1 (ko) * 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
US10160755B2 (en) * 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
US9938273B2 (en) * 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CN107550905B (zh) * 2017-09-11 2020-07-17 浙江永宁药业股份有限公司 多取代吡咯并吡啶类化合物的药物用途及其制备方法
WO2019057660A1 (en) * 2017-09-25 2019-03-28 Basf Se INDOLE AND AZAINDOLE COMPOUNDS HAVING 6-CHANNEL SUBSTITUTED ARYL AND HETEROARYL CYCLES AS AGROCHEMICAL FUNGICIDES
AU2018348241B2 (en) 2017-10-13 2023-01-12 Opna Bio SA Solid forms of a compound for modulating kinases
WO2019169306A1 (en) * 2018-03-01 2019-09-06 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress
CN113166139A (zh) * 2018-11-22 2021-07-23 百济神州有限公司 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途
AU2020271836A1 (en) * 2019-04-09 2021-10-28 Opna Bio SA Condensed azines for EP300 or CBP modulation and indications therefor
EP4340833A1 (fr) * 2021-05-21 2024-03-27 Centre National de la Recherche Scientifique (CNRS) Nouveaux derives azaindole en tant qu'agents antiviraux
WO2023245329A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multi-kinase inhibitors, compositions thereof, and methods of using the same
WO2023245327A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multiple kinase degraders, compositions comprising the degrader, and methods of using the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
US5019586A (en) * 1987-04-14 1991-05-28 Glaxo Group Limited Ketone derivatives
MX19185A (es) * 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP2886748B2 (ja) * 1992-09-17 1999-04-26 富士写真フイルム株式会社 写真用処理組成物及び処理方法
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB2298199A (en) * 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
WO1996032391A1 (de) 1995-04-11 1996-10-17 Lonza Ag Verfahren zur herstellung von azaindolen mit aktiviertem kupferchromit katalysator durch katalytische dehydrocyclisierung von alkyl-pyridylaminen (pyridopyridinen)
AU1517900A (en) 1998-10-28 2000-05-15 Eli Lilly And Company Photochemical process for making 1-deoxy-2-keto derivatives
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
DE10053122A1 (de) 1999-11-20 2001-05-23 Wella Ag Verfahren zur Herstellung von Indolen sowie die Verwendung dieser Indole in Färbemitteln
DE19955915C2 (de) 1999-11-20 2001-09-13 Wella Ag Tryptophanderivate und Tryptophanase enthaltende Haarfärbemittel sowie Verfahren zur enzymatischen Haarfärbung
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
JP2004509891A (ja) * 2000-09-22 2004-04-02 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン
EA200300717A1 (ru) 2000-12-22 2003-12-25 Уайт Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
CA2479205A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
EP1490364B1 (en) * 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
CA2495216A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
CA2503905A1 (en) 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
JP2006505552A (ja) 2002-10-09 2006-02-16 サイオス インク． ｐ３８キナーゼ阻害剤としてのアザインドール系誘導体
EP2295433A3 (en) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
WO2004101565A2 (en) 2003-05-16 2004-11-25 Eisai Co., Ltd. Jnk inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
FR2865313B1 (fr) 2004-01-15 2006-06-09 Diamecans Dispositif de manoeuvre bistable d'arbre mobile non traversant et coupe-circuit de batterie comprenant un tel dispositif
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
TWI465437B (zh) 2004-03-30 2014-12-21 Vertex Pharma 適合作為ｊａｋ及其它蛋白質激酶抑制劑之氮雜吲哚
CA2573362A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2608333A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
ECSP077280A (es) 2007-03-29
MA28810B1 (fr) 2007-08-01
EP1781654A1 (en) 2007-05-09
NZ553267A (en) 2010-09-30
MX2007001127A (es) 2007-07-11
US20080221119A1 (en) 2008-09-11
AU2005269386A1 (en) 2006-02-09
US7582637B2 (en) 2009-09-01
IL180790A0 (en) 2007-06-03
KR20070053237A (ko) 2007-05-23
US7361763B2 (en) 2008-04-22
WO2006015123A1 (en) 2006-02-09
EP2264033A1 (en) 2010-12-22
US20060030583A1 (en) 2006-02-09
US20090306056A1 (en) 2009-12-10
BRPI0513916A (pt) 2008-05-20
TNSN07027A1 (en) 2008-06-02
JP2008508303A (ja) 2008-03-21
CA2573362A1 (en) 2006-02-09
US7906648B2 (en) 2011-03-15

Similar Documents

Publication Publication Date Title
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20065678L (no) 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
NO20084712L (no) Nye farmasoytiske forbindelser
CA2620129C (en) Diaminopyrimidines as p2x3 and p2x2/3 modulators
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20083013L (no) Triazolopyridaziner som tyrosinkinasemodulatorer
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20082598L (no) ERBB-inhibitorer
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
NO20073183L (no) Tetrahydrokinolinanalgoer som muskariniske agonister
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20083639L (no) Aurorakinasemodulatorer og fremgangsmate for anvendelse
NO20085031L (no) Benzimidazolmodulatorer av VR1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application